• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

The Global Drug Market for Dermatological Conditions Associated With Ageing and Lifestyle is Estimated at US$1.8 Billion in 2005

Posted on: Thursday, 2 March 2006, 12:00 CST

Research and Markets (http://www.researchandmarkets.com/reports/c28592) has announced the addition of The Global Image Dermatology Drug Market, 2005-2012: High-Growth Opportunities in Aesthetic Medicine to their offering.

Examines the global market for aesthetic dermatologicals and specialty physician-dispensed drugs to treat conditions associated with deficits in physical image and form. Drugs such as botulinum toxins, retinoids, acid peels, 5-alpha reductase and lipase inhibitors associated with cutaneous ageing, photodamage, pigmentation defects, alopecia, and the lipodermal disorders of obesity and gynoid lipodystrophy are critically discussed to provide a detailed analysis of the high-growth market sector estimated at US$1.8 billion in 2005 and forecast to increase by 114% to US$3.9 billion by 2012. The report includes insights for product extension and optimization, sales forecasts to 2012, and impact of late-stage pipeline drugs on the market. Therapy area forecasting and illustrative market data and analysis is also presented to gain insight into top-performing products and therapy areas.

Objectives of the Report Briefing

The objectives of this report are to provide a detailed analysis of the global image dermatology drug market. Included in this study are analyses of key therapy areas, R&D programs, and innovating companies and products. The report briefing also aims to expand knowledge of the therapeutic areas and to highlight the role of antiageing medicines and lifestyle drugs in an increasingly ageing world population. It is hoped that the reader will benefit from market forecasts, pooled knowledge of recent industrial activities and events, and from analytical discourse, which is intended to stimulate growth and create new market opportunities.

Image dermatology is a high-growth market opportunity based on the increasing numbers of people turning to medical and surgical intervention to combat signs of cutaneous ageing and to correct perceived deficits in physical form.

Demand for therapeutic dermatologicals to treat conditions such as alopecia, cutaneous ageing, photodamage, skin pigmentation, and the lipodermal disorders of obesity and gynoid lipodystrophy (cellulite) will be driven by factors such as increasing worldwide ageing populations; unrelenting media fixation on physical improvement and restorative antiageing treatments; and innovation in the pharmaceutical industry to bring to market highly sophisticated efficacious drug treatments that serve to close the gap between medical and cosmetic interventions.

The global drug market for dermatological conditions associated with ageing and lifestyle is estimated at US$1.8 billion in 2005 and is forecast to increase by 114% to US$3.9 billion by 2012. In this report, The Global Image Dermatology Drug Market, 2005-2012: High-Growth Opportunities in Aesthetic Medicine, the reader will be introduced to a specialty pharmaceutical therapy area that is poised for significant expansion based on new pharmacotherapies to address cutaneous ageing, pigmentation disorders, obesity and gynoid lipodystrophy.

The report provides a detailed analysis of the sector to include insights for product extension and optimization, sales forecasts to 2012, and impact of late-stage pipeline drugs on the market. Each therapy area segment concludes with a summary of the key issues that are considered to affect growth and sustainability. An overview of R&D programs within the field is also highlighted showing products from preclinical to premarket authorization phases of development. Promising agents are discussed in relation to development status and commercial prospects.

Therapy area forecasting and illustrative market data and analysis are also presented to provide an insight into top-performing products and sales estimates to 2012. Therapy forecasting to 2020 is also detailed to enable the reader to make key assumptions about future markets and prospects, and utilize the data for proprietary predictive market modeling.

Companies Mentioned:

Abbott Laboratories Serono

Alizyme Shionogi

Allergan Solvay Pharmaceuticals

Amgen Stiefel Laboratories

Amylin Pharmaceuticals Targacept

Arena Pharmaceuticals Valeant Pharmaceuticals

Astellas Pharma Vernalis

Barrier Therapeutics Wyeth

Bertek Pharmaceuticals

Bioaccelerate

Biotecon Therapeutics

Biovitrium

Bristol-Myers Squibb

Chiron

Curis

Dainippon Sumitomo Pharmaceuticals

Eisai

Elan

Enhance Biotech

Epitan

Fasgen

Galderma

Genaera

Glades Pharmaceuticals

Glaxosmithkline

Genaderm

Inamed

Intercytex

Ipsen

Isolagen

Karo Bio

Ligand

Mentor

Merck

Merz Pharma

Metabolic Pharmaceuticals

Millennium

Nastech

Neurogen

Obagi Medical Products

Ortho-Mcneil Pharmaceuticals

Pfizer

Pherin Pharmaceuticals

Predix Pharma

Phytopharm

Roche

Sanofi-Aventis

Sapphiretherapeutics

For more information visit http://www.researchandmarkets.com/reports/c28592

Source: Business Wire

More News in this Category